Outlook Therapeutics, Inc. (OTLK)

Market Cap	55.54M
Revenue (ttm)	n/a
Net Income (ttm)	-75.37M
Shares Out	24.91M
EPS (ttm)	-4.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,061,565
Open	2.190
Previous Close	2.190
Day's Range	2.015 - 2.230
52-Week Range	0.870 - 12.850
Beta	0.54
Analysts	Strong Buy
Price Target	23.08 (+934.98%)
Earnings Date	Feb 12, 2025

About OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and change...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 13, 2016
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: OTLK
• Website: https://www.outlooktherapeutics.com

Analyst Forecast

According to 6 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price forecast is $23.08, which is an increase of 934.98% from the latest price.

Price Target

$23.08

(934.98% upside)

Analyst Consensus: Strong Buy